Research Analysts Offer Predictions for VRTX Q2 Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Equities research analysts at William Blair issued their Q2 2025 earnings per share estimates for shares of Vertex Pharmaceuticals in a report released on Tuesday, May 6th. William Blair analyst M. Minter forecasts that the pharmaceutical company will earn $3.95 per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share. William Blair also issued estimates for Vertex Pharmaceuticals’ Q3 2025 earnings at $4.16 EPS and Q4 2025 earnings at $4.54 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing the consensus estimate of $4.29 by ($0.23). The firm had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.85 billion. Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $4.76 EPS.

Several other brokerages also recently weighed in on VRTX. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday. Cantor Fitzgerald restated an “overweight” rating and set a $535.00 price objective on shares of Vertex Pharmaceuticals in a research report on Tuesday. BMO Capital Markets set a $545.00 target price on shares of Vertex Pharmaceuticals in a research report on Friday, January 31st. Canaccord Genuity Group upgraded shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and upped their price target for the stock from $408.00 to $424.00 in a research report on Tuesday, February 11th. Finally, Truist Financial lifted their price objective on Vertex Pharmaceuticals from $460.00 to $520.00 and gave the stock a “buy” rating in a report on Tuesday, February 11th. Thirteen analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $515.04.

Vertex Pharmaceuticals Stock Performance

NASDAQ VRTX opened at $425.30 on Thursday. The stock has a market capitalization of $109.34 billion, a price-to-earnings ratio of -193.32, a PEG ratio of 2.11 and a beta of 0.51. The stock has a 50-day moving average of $488.74 and a 200 day moving average of $465.90. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals has a twelve month low of $377.85 and a twelve month high of $519.88.

Insider Buying and Selling

In related news, EVP David Altshuler sold 3,231 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $500.00, for a total value of $1,615,500.00. Following the completion of the sale, the executive vice president now owns 26,512 shares in the company, valued at approximately $13,256,000. This trade represents a 10.86 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Ourania Tatsis sold 244 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total value of $111,034.64. Following the transaction, the executive vice president now owns 67,695 shares in the company, valued at $30,805,286.70. This trade represents a 0.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 4,315 shares of company stock valued at $2,121,012. 0.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the company. Blue Barn Wealth LLC acquired a new position in Vertex Pharmaceuticals in the 1st quarter valued at about $209,000. Altfest L J & Co. Inc. raised its stake in shares of Vertex Pharmaceuticals by 145.3% in the first quarter. Altfest L J & Co. Inc. now owns 1,646 shares of the pharmaceutical company’s stock valued at $798,000 after acquiring an additional 975 shares in the last quarter. Foster Dykema Cabot & Partners LLC boosted its stake in shares of Vertex Pharmaceuticals by 1.0% in the 1st quarter. Foster Dykema Cabot & Partners LLC now owns 61,455 shares of the pharmaceutical company’s stock valued at $29,795,000 after buying an additional 591 shares during the period. Chicago Partners Investment Group LLC grew its holdings in Vertex Pharmaceuticals by 17.5% during the 1st quarter. Chicago Partners Investment Group LLC now owns 948 shares of the pharmaceutical company’s stock worth $460,000 after acquiring an additional 141 shares in the last quarter. Finally, Commonwealth Financial Services LLC purchased a new position in Vertex Pharmaceuticals in the first quarter valued at $226,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.